CNS Pharmaceuticals (CNSP) Current Assets (2018 - 2025)
CNS Pharmaceuticals' (CNSP) quarterly Current Assets came in at $8.1 million in Q4 2025, down 6.42% YoY from $8.7 million in Q4 2024, and down 28.87% on a QoQ basis from $11.4 million in Q3 2025.
CNS Pharmaceuticals (CNSP) Current Assets (2018 - 2025) Analysis & Trends
CNS Pharmaceuticals (CNSP) has 8 years of Current Assets data on file, last reported at $8.1 million in Q4 2025.
- Quarterly Current Assets fell 6.42% year-over-year to $8.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $8.1 million (down 6.42% YoY) and the FY2025 annual result came in at $8.1 million, down 6.42% from the prior year.
- Current Assets eased to $8.1 million in Q4 2025, from $11.4 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $14.7 million in Q1 2022 to a low of $1.6 million in Q4 2023.
- A 5-year average of $8.8 million and a median of $8.7 million in 2022 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2023 — Current Assets tumbled 87.34% — and 2025, when it surged 756.94%.
- Tracing CNSP's Current Assets over 5 years: stood at $7.5 million in 2021, then jumped by 68.03% to $12.6 million in 2022, then plunged by 87.34% to $1.6 million in 2023, then soared by 444.16% to $8.7 million in 2024, then fell by 6.42% to $8.1 million in 2025.
- The last three Current Assets figures came in at $8.1 million (Q4 2025), $11.4 million (Q3 2025), and $14.1 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.90 Bn | 131.05 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 86.10 Bn | 78.11 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 65.56 Bn | 60.37 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 55.82 Bn | 50.68 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 42.14 Bn | 37.04 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 27.74 Bn | 9.35 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.38 Bn | 26.54 Bn | - | 1.76 Bn |
| 10 | CNS Pharmaceuticals | 2.68 Mn | -4.52 Mn | - | 8.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 8.10 Mn |
| Sep 30, 2025 | 11.39 Mn |
| Jun 30, 2025 | 14.14 Mn |
| Mar 31, 2025 | 13.72 Mn |
| Dec 31, 2024 | 8.66 Mn |
| Sep 30, 2024 | 7.39 Mn |
| Jun 30, 2024 | 2.15 Mn |
| Mar 31, 2024 | 1.60 Mn |
| Dec 31, 2023 | 1.59 Mn |
| Sep 30, 2023 | 2.06 Mn |
| Jun 30, 2023 | 6.07 Mn |
| Mar 31, 2023 | 6.97 Mn |
| Dec 31, 2022 | 12.56 Mn |
| Sep 30, 2022 | 8.70 Mn |
| Jun 30, 2022 | 11.40 Mn |
| Mar 31, 2022 | 14.73 Mn |
| Dec 31, 2021 | 7.48 Mn |
| Sep 30, 2021 | 11.16 Mn |
| Jun 30, 2021 | 13.88 Mn |
| Mar 31, 2021 | 12.79 Mn |